Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp151 | Neuroendocrinology & Growth Hormones | ECE2017

Growth hormone-releasing hormone (GHRH) antagonists, MIA-602 and MIA-690, inhibit survival and proliferation of human pleural mesothelioma cells

Villanova Tania , Gesmundo Iacopo , Taliano Marina , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Human malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm, arising from pleural mesothelial cells, generally due to asbestos exposure. Different growth factors are involved in the pathogenesis of MPM and in resistance to therapy; moreover, chemotherapy with cisplatin and antifolates, like pemetrexed (PEM), is the first-line treatment for inoperable MPM. Growth hormone-releasing hormone (GHRH), apart from stimulating GH secretion in the pituitary, exerts many...

ea0026p726 | Diabetes (epidemiology, pathophysiology) | ECE2011

Effects of the ghrelin gene products on glucose metabolism in C2C12 muscle cells

Grande Cristina , Settanni Fabio , Gesmundo Iacopo , Taliano Marina , Ghigo Ezio , Granata Riccarda

Type II diabetes is a clinical disorder of glucose and fat metabolism, caused by an inability of insulin to promote sufficient glucose uptake into adipose tissue and striated muscle and to prevent glucose output from the liver. Skeletal muscle is an important element for the maintenance of glucose homeostasis because it can increase, after stimulation, glucose uptake from the blood. In previous experiments we found that acylated ghrelin (AG), unacylated ghrelin (UAG), obestati...